Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000693477 | SCV000821348 | uncertain significance | Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 | 2023-12-27 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 547 of the SDHA protein (p.Lys547Arg). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SDHA-related conditions. ClinVar contains an entry for this variant (Variation ID: 572160). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SDHA protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV003338734 | SCV004059187 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-08-17 | criteria provided, single submitter | clinical testing | The p.K547R variant (also known as c.1640A>G), located in coding exon 12 of the SDHA gene, results from an A to G substitution at nucleotide position 1640. The lysine at codon 547 is replaced by arginine, an amino acid with highly similar properties. Functional studies indicate that this mutation impairs succinate dehydrogenase activity and interferes with SDHAF2 binding (Ma Y et al. Free Radic Biol Med, 2019 Apr;134:458-467). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Baylor Genetics | RCV003472210 | SCV004200640 | uncertain significance | Dilated cardiomyopathy 1GG | 2023-05-26 | criteria provided, single submitter | clinical testing |